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Abstract
Introduction: To describe the use of combined preoperative imaging and intraoperative
parathyroid hormone as a novel approach in the surgical management of a patient with tertiary
hyperparathyroidism associated with X-linked hypophosphatemic rickets.
Case presentation: We present the first documented description of combined preoperative
imaging and intraoperative parathyroid hormone as well as a review of the literature surrounding the
surgical management of tertiary hyperparathyroidism in the setting of X-linked hypophosphatemic
rickets.
A 23 year-old female with X-linked hypophosphatemic rickets and renal impairment presented with
symptomatic hypercalcemia and tertiary hyperparathyroidism. She had failed medical management
and presented for surgical evaluation. Technitium-99 m Sestamibi SPECT imaging and parathyroid
ultrasound were used to localize the enlarged parathyroid glands preoperatively. Intraoperative
findings correlated well with pre-operative imaging. She underwent successful subtotal parathy-
roidectomy for four-gland hyperplasia, using intraoperative parathyroid hormone guidance. Despite
severe post-operative bone hunger, her serum calcium normalized and she experienced resolution of
her preoperative symptoms.
Conclusion: X-linked hypophosphatemic rickets is an uncommon disorder of phosphate
metabolism resulting in bone deformity. Patients are predisposed to the development of secondary
hyperparathyroidism due to chronic vitamin D supplementation which may progress to tertiary
hyperparathyroidism with autonomous parathyroid function. Preoperative evaluation with
Technitium-99 m Sestamibi SPECT and ultrasound imaging, as well as the use of intraoperative
parathyroid hormone are effective in guiding surgical resection. Subtotal parathyroidectomy with
cryopreservation is indicated to produce operative cure and limit the risk of recurrence. Although
these patients are susceptible to severe postoperative bone hunger, appropriate supplementation
with intravenous and oral calcium can minimize hypocalcemic symptoms.
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X-linked hypophosphatemic rickets (XLHR) is a rare
dominant hereditary bone disorder characterized by
excessive renal phosphate excretion and impaired bone
mineralization [1]. Patients with XLHR present with
hypophosphatemia, short stature, and osteomalacia, with
a characteristic “bowing” of the femur [1]. They may also
present with enthesopathy and excessive tooth decay.
Plasma calcitriol levels are often paradoxically decreased,
with preserved calcidiol levels, suggesting impaired
vitamin D synthesis. Medical treatment of XLHR involves
high dose oral phosphate. Initially, phosphate repletion
leads to hypocalcemia and further calcitriol depletion,
causing secondary hyperparathyroidism (HPT) and
worsening bone disease. Oral calcitriol is given to counter-
act secondary HPT. However, excessive doses of calcitriol
may cause hypercalciuria and nephrocalcinosis. Persistent
secondary HPT may also lead to tertiary (autonomous)
HPT, with associated symptomatic hypercalcemia [2,3].
The preoperative assessment and surgical management of
tertiary HPT associated with XLHR has not been well
characterized. We describe the preoperative localization
and use of intraoperative quick PTH (IOPTH) to guide
successful subtotal parathyroidectomy in a case of XLHR-
associated tertiary HPT.
Case presentation
A 23 year old Caucasian American female with a known
diagnosis of XLHR presented with symptomatic hyper-
calcemia and tertiary HPT. As a child, she had been treated
with high dose phosphate and calcitriol supplementation
which resulted in renal insufficiency and subsequent
hypertension. Recently, she developed bone pain in her
back and lower extremities, with increasing fatigue. She
was found to have a calcium level of 10.7 mg/dl (normal
range 8.5-10.5) with a PTH of 997 pg/ml (normal range
12-65) and was diagnosed with tertiary HPT.
Additional past medical history was significant for a left
femoral osteotomy performed for bowing deformity at the
age of eight. She underwent a Cesarean section when she
was 20, and her pregnancy was complicated by pre-
eclampsia. She had no prior fractures or kidney stones.
Her medications included labetalol, losartan and 500 mg
oral phosphorus. She had been taking 0.25 mcg calcitriol
daily, which was recently discontinued. Her family history
was significant for multiple family members with XLHR
(Figure 1), including her 3 year old son.
Onphysicalexamination,shewas162.5cminheight,85.3kg
(BMI 31.5). Heart rate was 72 beats per minutes and blood
pressure was 150/110 mmHg. She had no band keratopathy.
Her thyroid was normal in size with no dominant nodules
and she had no cervical lymphadenopathy. She had bilateral
bowing of the lower extremities. Serum calcium and PTH
levels were 10.7 mg/dl and 1126 pg/ml, respectively. The
remainder of her laboratory values were within normal
limits including phosphate 2.7 mg/dl, 25-hydroxyvitamin
D 25 pg/ml, 1, 25-dihydroxyvitamin D 22 pg/ml, TSH
3.161 µIU/ml, and T4 7.8 µg/dl. A recent bone density study
demonstrated low normal values of bone density for her age.
Preoperative evaluation included Technetium-99 m Sesta-
mibi SPECT imaging as well as a complete thyroid and
parathyroid ultrasound. The Sestamibi scan showed focal
intense tracer uptake on delayed images in the right
tracheoesophageal groove,as wellas increased traceruptake
suggestive of an enlarged left sided gland (Figure 2).
Ultrasound revealed a normal appearing thyroid gland,
with bilateral enlarged superior parathyroid glands in the
tracheoesophageal groove. Neither inferior parathyroid
gland was visualized (Figure 3).
A bilateral parathyroid exploration with subtotal para-
thyroidectomy was planned. Baseline IOPTH was
1298 pg/ml (normal <65 pg/ml). Intraoperative findings
correlated with preoperative imaging, with two large
superior parathyroid glands and moderately enlarged
inferior parathyroid glands (Figure 4). Approximately
100 mg parathyroid tissue was sent for cryopreservation,
and approximately 40 mg of the most normal-appearing
lower parathyroid was left as an intact remnant.
Ten minutes after removal of the last specimen, the PTH
level was 114 pg/ml. Of note, the surgical pathology report
(supplementalfigure)describesallfourparathyroidglands
as “enlarged and hypercellular”.
Figure 1. Pedigree representing the dominant
X-linked inheritance pattern of XLHR. Our patient is
denoted by the asterix (*). Note that neither offspring
of the patient’s paternal uncle who carries the trait are
affected.
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hypocalcemia and was initially maintained on an intra-
venouscalciumdrip.Hercalciumlevelnadirwas5.7mg/dl,
but slowly corrected over 72 hours to 8.7 mg/dl. She was
also treated with oral calcium (2 g calcium carbonate four
times daily for 72 hours, then three times daily) and
vitamin D supplementation (calcitriol 0.75 mcg daily).
She was discharged on postoperative day six with no
symptomatic hypocalcemia. Two weeks post-operatively,
her calcium level was 9.3 mg/dl, and she had complete
resolution of all preoperative symptoms. At follow-up
both six and ten months later she remained asymptomatic
and her calcium and phosphate levels were normal
(9.0 and 2.8 mg/dL, respectively), suggesting norecurrence
of tertiary hyperparathyroidism. She had a mild elevation
of her PTH (136 mg/dL) in the setting of chronic renal
insufficiency (creatinine 1.9).
Discussion
XLHR is a rare dominant hereditary disorder which occurs
in approximately 1 per 20,000 individuals. The patho-
genesis of this disease is not fully understood. Cross-
transplantation studies using a mouse model (Hyp
mouse) demonstrate that the primary phosphate transport
defect results from a circulating factor that is extrinsic to
the kidney [4]. Thought to be a phosphatonin, this factor
promotes phosphate excretion by causing under-
expression of the renal sodium phosphate cotransporter
[5]. In several forms of hypophosphatemic rickets, similar
phosphaturic factors such as fibroblast growth factor
23 (FGF23), frizzled-related protein 4 (FRP 4), matrix
extracellular phosphoglycoprotein (MEPE), FGF-7, and
stanniocalcin 1, 2 (STC1, 2) have been identified [6,7]. In
XLHR, mutations in the osteoblast phosphate regulating
endopeptidase gene on the X chromosome (PHEX) lead
to failure to inactivate a phosphaturic factor resulting
in the clinical sequelae of hypophosphatemia and hyper-
phosphaturia, slow growth, bone deformities, muscle
weakness, and paresthesias [8,9]. Unfortunately, chronic
supplementation with phosphorus and vitamin D often
results in hypocalcemia, leading to secondary HPT.
In the presence of renal impairment, the parathyroids
can become autonomously functional, leading to
tertiary HPT and hypercalcemia. In these cases, surgical
Figure 2. Technetium-99 m Sestamibi SPECT imaging
demonstrates focal uptake of tracer in bilateral
tracheoesophageal grooves, consistent with bilateral
superior parathyroid gland enlargement. (A) and (C) are
represent slices through the left TE groove and more
caudal right TE groove parathyroids, respectively. (B) and (D)
are matching late images.
Figure 3. Representative images of the ultrasound of the
thyroid and parathyroid glands are shown. (A) demonstrates a
sagittal view of the right lobe of the thyroid, and a mass
measuring 2.93 × 1.23 cm is demarcated by lines 1 and 2 is
noted posteriorly in the tracheoesophageal groove.
(B) demonstrates a 2.63 × 0.69 cm mass in
tracheoesophageal groove posterior to the left
lobe of the thyroid. (C) shows a transverse view of the
entire thyroid gland, with the hypoechoic masses noted
posteriorly (R,L).
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subsequent hypercalcemic symptoms [10].
The literature regarding the optimal surgical treatment of
tertiary HPT is controversial. Although resection of single
or double adenoma has been found to be effective in some
cases [11], many authors suggest that subtotal parathy-
roidectomy is required for operative cure [12,13]. Addi-
tionally, the rate of recurrence appears to be lower with
subtotal parathyroidectomy [14]. Importantly, a thorough
review of the literature reveals a paucity of data regarding
surgical management of tertiary HPT associated with
XLHR. The largest series was a retrospective study contain-
ing six patients with different surgical approaches (2-, and
3-gland, total parathyroidectomy), and neither the
preoperative evaluation nor the use of IOPTH was
addressed. In addition, less than subtotal parathyroi-
dectomy led to recurrence of HPT in one patient [10].
The role of preoperative parathyroid localization includ-
ing Technetium-99 m Sestamibi SPECT imaging and
parathyroid ultrasound in tertiary HPT is unclear, and its
efficacy has been questioned in recent studies [15,16].
Sestamibi scans are twice as likely to identify single or
double parathyroid adenomas as multiple gland hyper-
plasia, which makes high-resolution ultrasonography an
excellent complementary study [17,18]. In our case,
bilateral dominant superior enlarged glands were correctly
identified using both Sestamibi and ultrasound. Imaging
was also able to exclude supernumerary ectopic glands.
The smaller hyperplastic inferior parathyroid glands were
not identified by preoperative imaging, confirming the
necessity of bilateral, four-gland exploration and subtotal
parathyroidectomy.
Although the use of intraoperative PTH is widely
established in primary HPT, guidelines for its use in
secondary and tertiary HPT remain a source of debate. In
primary HPT because of the short half-life of PTH (about
four minutes), it has been established that an IOPTH
decrease of >50% and into the normal range post-
resection is predictive of operative cure [11]. Further,
recent studies indicate IOPTH is highly predictive of
successful surgical correction of secondary and tertiary
HPT, particularly in the setting of renal impairment
[19,20]. However, there is a lack of evidence for its
applicability in subtotal parathyroidectomy in patients
with tertiary HPT associated with XHLR. In our case, we
documented a 90% drop in PTH after subtotal resection
with normal calcium levels ten months post-operatively,
indicating that she was surgically cured of her tertiary
hyperparathyroidism, The mild elevation of her PTH was
likely reflective of secondary hyperparathyroidism due to
chronic renal insufficiency or vitamin D deficiency.
Conclusion
XLHRisararehereditarydiseasecharacterizedbyphosphate
wasting, impaired bone mineralization and secondary HPT
that may progress to tertiary HPT with symptomatic
hypercalcemia. We present the first case of XLHR-associated
tertiary HPT using preoperative parathyroid localization
and IOPTH monitoring to guide successful subtotal
parathyroidectomy. Although this is a rare condition,
appropriately guided surgical intervention provides durable
cure of HPT and significant symptom relief.
Abbreviations
HPT, hyperparathyroidism; IOPTH, intraoperative quick
PTH; PTH, parathyroid hormone; XLHR, X-linked hypo-
phosphatemic rickets.
Figure 4. (A) Intraoperative photograph demonstrating the
enlarged right side superior parathyroid gland (P). Normal
appearing thyroid tissue (T) is retracted medially for
exposure. (B) Appearance of the specimens sent for
pathological examination. Note the enlarged bilateral superior
glands and the smaller inferior gland. Only one inferior gland
was sent for permanent section; the remaining gland was
divided in half, with one half left in situ and the other sent for
cryopreservation.
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We deeply regret that we were unable to reach the patient
to obtain her consent after attempting to contact her for
5 consecutive days through both her home and cell
phones. It does not appear that she has the same contact
information as what we have on file, and she is not a local
(Pittsburgh) resident.
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